Literature DB >> 11606857

Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma.

N H Park1, Y H Chung, K H Youn, B C Song, S H Yang, J A Kim, H C Lee, E Yu, Y S Lee, S G Lee, K W Kim, D J Suh.   

Abstract

Mutation of p53 is a poor prognostic indicator of hepatocellular carcinoma (HCC). Although poor histologic differentiation of HCC has been associated with p53 mutations, the exact reasons for unfavorable clinical outcomes in patients with HCC remain to be clarified. In this study, we evaluate the association between p53 mutation and histopathologic features of HCCs, as well as tumor recurrences and survival. We examined 20 HCCs and surrounding liver tissues from patients who underwent surgical resection, and we performed direct sequencing of p53 gene. p53 mutations were found in 9 of 20 HCCs; none were found in the surrounding liver tissue. p53 mutations were frequent in large, multinodular, and poorly differentiated HCCs. Five of 9 with p53 mutation (in contrast, none of 11 with wild-type mutation) showed microvascular invasions. Hepatocellular carcinoma recurred in 6 of 9 with p53 mutation, in contrast to only 2 of 11 with wild-type mutation. The 1-year survival rate with p53 mutation was significantly lower than that with wild-type. In conclusion, it is suggested that p53 mutations tend to be commonly associated with microvascular invasions, which may result in micrometastasis, followed by frequent recurrences.

Entities:  

Mesh:

Year:  2001        PMID: 11606857     DOI: 10.1097/00004836-200111000-00011

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  19 in total

1.  A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC.

Authors:  Xia Sheng; Yuan Ji; Guo-Ping Ren; Chang-Li Lu; Jing-Ping Yun; Li-Hong Chen; Bin Meng; Li-Juan Qu; Guang-Jie Duan; Qing Sun; Xin-Qing Ye; Shan-Shan Li; Jing Yang; Bing Liao; Zhan-Bo Wang; Jian-Hua Zhou; Yu Sun; Xue-Shan Qiu; Lei Wang; Zeng-Shan Li; Jun Chen; Chun-Yan Xia; Song He; Chuan-Ying Li; En-Wei Xu; Jing-Shu Geng; Chao Pan; Dong Kuang; Rong Qin; Hong-Wei Guan; Zhan-Dong Wang; Li-Xing Li; Xi Zhang; Han Wang; Qian Zhao; Bo Wei; Wu-Jian Zhang; Shao-Ping Ling; Xiang Du; Wen-Ming Cong
Journal:  Hepatol Int       Date:  2020-12-28       Impact factor: 6.047

2.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

3.  TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Jun Xue
Journal:  Tumour Biol       Date:  2014-02

Review 4.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

Review 5.  Chromosomal aberrations related to metastasis of human solid tumors.

Authors:  Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

6.  Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.

Authors:  Kevin S Brown
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

7.  The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds.

Authors:  Xiaohui Duan; Yi Cai; Tingting He; Xiaoliang Shi; Juan Zhao; Hui Zhang; Yao Shen; Hongjian Zhang; Heng Zhang; Wenbin Duan; Bo Jiang; Xianhai Mao
Journal:  J Gastrointest Oncol       Date:  2021-08

8.  TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-10       Impact factor: 7.293

9.  Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.

Authors:  Umberto Cillo; Alessandro Vitale; Marco Bassanello; Patrizia Boccagni; Alberto Brolese; Giacomo Zanus; Patrizia Burra; Stefano Fagiuoli; Fabio Farinati; Massimo Rugge; Davide Francesco D'Amico
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

10.  Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.